Keywords
Jaundice
Biliary complications
Common bile duct dilation
Cross-sectional imaging
How to Cite
Abstract
Introduction: This study aims to differentiate whether jaundice in patients with alcoholic hepatitis (AH) is due to alcohol-related liver disease or underlying biliary pathology, including choledocholithiasis, primary sclerosing cholangitis, primary biliary cholangitis, benign strictures, cholangiocarcinoma, or pancreatic cancer. Accurate differentiation is crucial for appropriate treatment decisions.
Methods: A non-interventional retrospective study examined patients admitted to our institute for presumed alcohol-related hepatitis management from 2016 to 2023. The primary outcome was the occurrence of biliary processes, whether benign or malignant, in patients managed for alcohol-related hepatitis within 90 days. Secondary outcomes assessed bilirubin level trends over seven days to evaluate steroid effects on alcohol-related hepatitis and predict underlying biliary processes. Variables were analyzed using bivariate and multivariate logistic regression with biliary process as the dependent variable.
Results: Our study revealed that patients with alcohol-related hepatitis and jaundice who had dilated common bile duct (CBD) or pancreatic duct (PD) on cross-sectional imaging were more likely to have biliary processes regardless of cholecystectomy history p-value 0.007 (CI 0.03-0.242) OR 7.5 and p-value 0.001 (CI 0.58-1.34), OR 1.2 respectively. However, there was no correlation between biliary process incidence and various demographic or clinical factors.
Conclusion: Cross-sectional imaging should be routinely used to evaluate biliary tree conditions in alcohol-related hepatitis patients with jaundice who have dilated CBD, particularly those with previous cholecystectomy or gallstones on imaging studies. This systematic approach enables early identification of underlying biliary issues and facilitates prompt, appropriate management decisions.
References
1. Suen LW, Makam AN, Snyder HR, Repplinger D, Kushel MB, Martin M, et al. National Prevalence of Alcohol and Other Substance Use Disorders Among Emergency Department Visits and Hospitalizations: NHAMCS 2014-2018. J Gen Intern Med. 2022: 2420 [PMID: 34518978, https://doi.org/10.1007/s11606-021-07069-w]
2. Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018: 872 [PMID: 29579356, https://doi.org/10.1002/hep.29887]
3. Moon AM, Yang JY, ASt B, Bataller R, Peery AF. Rising Mortality From Alcohol-Associated Liver Disease in the United States in the 21st Century. Am J Gastroenterol. 2020: 79 [PMID: 31688021, https://doi.org/10.14309/ajg.0000000000000442]
4. Lee BP, Dodge JL, Leventhal A, Terrault NA. Retail Alcohol and Tobacco Sales During COVID-19. Ann Intern Med. 2021: 1027 [PMID: 33646843, https://doi.org/10.7326/M20-7271]
5. Gonzalez HC, Zhou Y, Nimri FM, Rupp LB, Trudeau S, Gordon SC. Alcohol-related hepatitis admissions increased 50. Liver Int. 2022: 762 [PMID: 35094494, https://doi.org/10.1111/liv.15172]
6. Deutsch-Link S, Jiang Y, Peery AF, Barritt AS, Bataller R, Moon AM. Alcohol-Associated Liver Disease Mortality Increased From 2017 to 2020 and Accelerated During the COVID-19 Pandemic. Clin Gastroenterol Hepatol. 2022: 2142 [PMID: 35314353, https://doi.org/10.1016/j.cgh.2022.03.017]
7. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020: 306 [PMID: 31314133, https://doi.org/10.1002/hep.30866]
8. Torbenson M, Yeh MM, Abraham SC. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis. Am J Surg Pathol. 2007: 1410 [PMID: 17721197, https://doi.org/10.1097/PAS.0b013e318053d122]
9. Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017: 101 [PMID: 28503557, https://doi.org/10.21037/hbsn.2017.01.02]
10. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011: 173 [PMID: 21488076, https://doi.org/10.1002/hep.24351]
11. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007: 1221 [PMID: 17689296, https://doi.org/10.1016/j.cgh.2007.05.020]
12. Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control. 2001: 959 [PMID: 11808716, https://doi.org/10.1023/a:1013747228572]
13. Luo G, Hao NB, Hu CJ, Yong X, Lu MH, Cheng BJ, et al. HBV infection increases the risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2013: 529 [PMID: 23306552, https://doi.org/10.1007/s10552-012-0144-2]
14. Brown LM. Epidemiology of alcohol-associated cancers. Alcohol. 2005: 161 [PMID: 16054977, https://doi.org/10.1016/j.alcohol.2005.03.008]
15. Forrest E, Mellor J, Stanton L, Bowers M, Ryder P, Austin A, et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials. 2013: 262 [PMID: 23958271, https://doi.org/10.1186/1745-6215-14-262]
16. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006: 230 [PMID: 16844493, https://doi.org/10.1016/S0140-6736(06)69044-2]
17. Rizvi A, Sethi A, Poneros J, Visrodia KH. Does incidentally detected common bile duct dilation need evaluation? Cleve Clin J Med. 2022: 315 [PMID: 35649563, https://doi.org/10.3949/ccjm.89a.21029]
18. Smith I, Monkemuller K, Wilcox CM. Incidentally Identified Common Bile Duct Dilatation: A Systematic Review of Evaluation, Causes, and Outcome. J Clin Gastroenterol. 2015: 810 [PMID: 26302495, https://doi.org/10.1097/MCG.0000000000000394]
19. Oddi R, Rosciano G. Sulla esistenza di speciali gangli nervosi in prossimità dello sfintere del coledoco. Monitore Zoologico Italiano. 1894: 216
20. Latenstein CSS, Wennmacker SZ, Jong JJ, Laarhoven C, Drenth JPH, Reuver PR. Etiologies of Long-Term Postcholecystectomy Symptoms: A Systematic Review. Gastroenterol Res Pract. 2019: 4278373 [PMID: 31110517, https://doi.org/10.1155/2019/4278373]
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 ASIDE Gastroenterology